Clinical Trial Update: Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) [Phase 3]

View source ↗

Summary

Phase 3 trial update for losmapimod in facioscapulohumeral muscular dystrophy (FSHD) indicates the study was terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• Losmapimod (losmapimod)

Snippet

Sponsor: Fulcrum Therapeutics | Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 3 | Status: TERMINATED | Results posted: 2025-11-10